Condition Results Operations Refer company Annual Report Form 10-K year ended December 31 2016 2016 Annual Report management discussion analysis financial condition results operations company The following management discussion analysis financial condition results operations company three months ended March 31 2017 RESULTS OF OPERATIONS Baxter income continuing operations three months ended March 31 2017 totaled 273 million 0.50 per diluted share compared 3.4 billion 6.13 per diluted share three months ended March 31 2016 Income continuing operations three months ended March 31 2017 included special items decreased income continuing operations 45 million 0.08 per diluted share discussed Income continuing operations three months ended March 31 2016 included special items increased income continuing operations 3.2 billion 5.77 per diluted share discussed Special Items The following table provides summary company special items related impact line item company results continuing operations three months ended March 31 2017 2016 Three months ended March 31 millions 2017 2016 Gross Margin Intangible asset amortization expense 38 40 Business optimization items 1 16 12 Product-related items 2 12 Total Special Items 54 40 Impact Gross Margin Ratio 2.2 pts 1.7 pts Marketing Administrative Expenses Business optimization items 1 15 3 Separation-related costs 3 7 18 Historical reserve adjustments 4 12 Total Special Items 10 21 Impact Marketing Administrative Expense Ratio 0.4 pts 0.9 pts Research Development Expenses Business optimization items 1 2 Total Special Items 2 Other Expense Income Net Loss debt extinguishment 5 101 Net realized gains Retained Share transactions 6 3,243 Total Special Items 3,142 Income Tax Expense Benefit Impact special items 17 107 Total Special Items 17 107 Impact Effective Tax Rate 1.7 pts 21.5 pts 23 Intangible asset amortization expense identified special item facilitate evaluation current past operating performance similar management internally assesses performance Additional special items identified highly variable difficult predict size may substantially impact company reported operations period Management believes providing separate impact items company results accordance GAAP United States may provide complete understanding company operations facilitate fuller analysis company results operations particularly evaluating performance one period another This information considered addition substitute information prepared accordance GAAP 1 The company's results 2017 included net charge 29 million related business optimization initiatives This included net charge 3 million related restructuring activities 21 million costs implement business optimization programs primarily included external consulting project employee costs 5 million accelerated depreciation associated facilities closed The 3 million net restructuring included net 2 million employee termination costs 1 million related contract termination costs The company results 2016 included net charge 15 million related business optimization initiatives This included net charge 4 million related restructuring activities 4 million costs implement business optimization programs primarily included external consulting fees 7 million Gambro integration costs The 4 million net restructuring charges related employee termination costs 2 The company results first quarter 2016 included benefit 12 million related adjustment SIGMA SPECTRUM infusion pump reserves 3 The company's results 2017 2016 included costs incurred related Baxalta separation totaling 7 million 18 million respectively 4 The company's results 2017 included benefit 12 million related adjustment company's historical rebates discounts reserve 5 The company results 2016 included net debt extinguishment loss totaling 101 million related March 2016 debt-for-equity exchange certain company indebtedness See Note 8 within Item 1 additional details 6 The company results 2016 included net realized gains 3.2 billion related debt-for-equity exchanges company retained shares Baxalta certain company indebtedness NET SALES Three months ended March 31 Percent change millions 2017 2016 At actual currency rates At constant currency rates US Cyclophosphamide Strategic Product Exits Renal 896 898 0 1 0 1 Hospital Products 1,579 1,477 7 7 2 1 Total net sales 2,475 2,375 4 5 1 1 Three months ended March 31 Percent change millions 2017 2016 At actual currency rates At constant currency rates US Cyclophosphamide Strategic Product Exits International 1,372 1,383 1 0 0 2 United States 1,103 992 11 11 2 0 Total net sales 2,475 2,375 4 5 1 1 Foreign currency unfavorably impacted net sales one percentage point first quarter 2017 compared prior period principally due strengthening U.S Dollar relative Euro Mexican Peso British Pound Chinese Yuan well certain currencies The comparisons presented constant currency rates reflect comparative local currency sales prior period foreign exchange rates This measure provides information change net sales assuming foreign currency exchange rates changed prior current period The company believes non-GAAP measure change net sales constant currency rates used conjunction GAAP measure change net sales actual currency rates may provide 24 complete understanding company operations facilitate fuller analysis company results operations particularly evaluating performance one period another During 2016 company made strategic decision exit select products certain markets including Venezuela India Turkey Overall items negative impact company net sales growth rate one percentage point first quarter 2017 The company also presenting impact generic competition U.S cyclophosphamide enhance comparability periods better identify operating trends The impact generic competition U.S cyclophosphamide also negative impact company net sales growth rate one percentage point first quarter 2017 Franchise Net Sales Reporting The Renal segment includes sales company peritoneal dialysis PD hemodialysis HD continuous renal replacement therapies CRRT additional dialysis services The Hospital Products segment includes four commercial franchises Fluid Systems Integrated Pharmacy Solutions Surgical Care Other Fluid Systems includes sales company intravenous IV therapies infusion pumps IV administration sets Integrated Pharmacy Solutions includes sales company premixed oncology drug platforms nutrition products pharmacy compounding services Surgical Care includes sales company inhaled anesthesia products critical care products well biological products medical devices used surgical procedures hemostasis tissue sealing adhesion prevention Other includes sales primarily company pharmaceutical partnering business The following summary net sales commercial franchise reported constant currency basis along impact significant non-operational items Three months ended March 31 Percent change millions 2017 2016 At actual currency rates At constant currency rates US Cyclophosphamide Strategic Product Exits Total Renal net sales 896 898 0 1 0 1 Fluid Systems 585 524 12 12 0 1 Integrated Pharmacy Solutions 552 556 1 0 3 1 Surgical Care 334 305 10 10 0 1 Other 108 92 17 18 Total Hospital Products net sales 1,579 1,477 7 7 2 1 Net sales Renal segment first quarter 2017 comparable prior period Excluding impact foreign currency sales increased 1 driven continued growth PD patients adoption company new Automated Peritoneal Dialysis Cyclers APD AMIA U.S HomeChoice CLARIA international markets Increased sales globally company CRRT also contributed growth quarter Sales growth quarter partially offset lower sales HD products internationally driven reduced volumes increased pricing pressures Certain international strategic market exits negatively impacted Renal net sales 1 quarter expected negatively impact full year Renal net sales approximately 50 million compared 2016 Net sales Hospital Products segment increased 7 first quarter 2017 compared prior period reported constant currency basis Certain international strategic market exits negatively impacted hospital products net sales 1 quarter expected negatively impact full year net sales approximately 50 million compared 2016 In addition reduced U.S sales cyclophosphamide negatively impacted net sales 2 quarter The principal drivers impacting net sales following In Fluid Systems franchise sales increased 12 first quarter 2017 constant currency basis driven pricing volumes U.S IV solutions contributed approximately eight percentage points growth rate This increase also positively impacted increased sales company IV access administrative sets reflecting on-going pull company growing SPECTRUM infusion pump base 25 In Integrated Pharmacy Solutions franchise sales comparable constant currency basis driven pricing volume company nutritional therapies contributing approximately two percentage points favorable volume pre-mixed injectable drugs contributing approximately two percentage points These increases offset decreased U.S sales cyclophosphamide generic oncology drug due entry competitors market U.S sales cyclophosphamide declined 60 million first quarter 2016 47 million first quarter 2017 contributed approximately three percentage points decline The company expects U.S sales cyclophosphamide continue decline 2017 due additional competition entering market In Surgical Care franchise sales increased 10 first quarter 2017 constant currency basis driven strong volumes pricing U.S company portfolio anesthetic critical care products This increase principally due increased volume TransDerm Scop Brevibloc fast-acting IV beta blocker The increased TransDem Scop volume result temporary supply disruption related alternative product These items positively impacted net sales approximately seven percentage points Improved international volumes company biosurgery products also contributed approximately three percentage points sales growth In Other franchise sales increased 18 first quarter 2017 constant currency basis driven favorable volumes products manufactured Baxter behalf pharmaceutical partner partially offset reduced revenues related company manufacturing supply agreement Baxalta Gross Margin Expense Ratios Three months ended March 31 percentage net sales 2017 2016 Change Gross margin 42.1 40.6 1.5 pts Marketing administrative expenses 23.0 27.0 4.0 pts Gross Margin The special items identified unfavorable impact approximately 2.2 1.7 percentage points gross margin percentage first quarters 2017 2016 respectively Refer Special Items caption additional detail Excluding impact special items gross margin ratio increased due improved pricing select areas portfolio favorable product geographic mix benefit company business transformation initiatives aimed simplifying portfolio drive efficiency reduce costs Marketing Administrative Expenses The special items identified favorable impact approximately 0.4 0.9 percentage points marketing administrative expense ratio first quarters 2017 2016 respectively Refer Special Items caption additional detail Excluding impact special items marketing administrative expenses ratio first quarter 2017 declined due actions taken company rebase cost structure focus expense management These savings partially offset decreased benefits marketing administrative expenses ratio lower transition service income agreement Baxalta services continues wind Research Development Three months ended March 31 Percent millions 2017 2016 change Research development expenses 128 136 6 As percentage net sales 5.2 5.7 Research development expenses decreased six percent first quarter 2017 result Company efforts optimize overall research development expenditures reduce infrastructure related expenses shift investment new product development 26 Business Optimization Items Beginning second half 2015 company initiated actions transform costs structure enhance operational efficiency These efforts include restructuring organization optimizing manufacturing footprint R&D operations supply chain network employing disciplined cost management centralizing streamlining certain support functions Through March 31 2017 company incurred pretax costs 439 million related actions The costs consisted primarily employee termination costs implementation costs accelerated depreciation The company expects incur additional pretax costs approximately 360 million capital expenditures 90 million related initiatives end 2018 These costs primarily include employee termination costs implementation costs accelerated depreciation The company expects approximately 5 percent remaining charges non-cash These actions aggregate expected provide future annual pretax savings approximately 860 million The savings actions impact cost sales marketing administrative expenses research development expenses Approximately 85 percent expected annual pretax savings expected realized end 2018 remainder end 2020 Refer Note 7 Item 1 additional information regarding company business optimization initiatives Net Interest Expense Net interest expense 14 million 28 million first quarters 2017 2016 respectively The decrease first quarter 2017 primarily driven lower outstanding debt result first quarter 2016 debt-for-equity exchanges extinguished 3.65 billion debt well reduced coupon rates resulting third quarter 2016 debt issuance See Note 8 within Item 1 additional details debt extinguishments Other Expense Income Net Other expense income net expense 2 million first quarter 2017 income 3.2 billion first quarter 2016 respectively Excluding impact 3.2 billion net realized gain Retained shares transactions 101 million debt extinguishment loss expense income net decreased 29 million 2017 compared 2016 The decrease attributable income 2016 9 million dividend Retained Shares 9 million income related foreign currency fluctuations principally related intercompany receivables payables monetary assets denominated foreign currency In addition company recognized investment impairment losses 7 million first quarter 2017 Segment EBITDA The company uses income continuing operations net interest expense income tax expense depreciation amortization expense Segment EBITDA segment basis make resource allocation decisions assess ongoing performance company business segments Refer Note 14 within Item 1 summary financial results segment The following summary significant factors impacting segments financial results Renal Segment EBITDA 199 million 122 million first quarters 2017 2016 respectively The increase 2017 driven lower research development costs company realigned allocations research development costs based project spend attributable segments higher gross margins due product mix lower marketing administrative expenses Renal segment benefited company business optimization programs continued focus reducing discretionary spending This growth partially offset unfavorable foreign currency Hospital Products Segment EBITDA 564 million 509 million first quarters 2017 2016 respectively This increase driven higher net sales principally Fluid Systems Surgical Care franchises lower marketing administrative expenses cost savings realized company business optimization programs continued focus reducing discretionary spending This growth partially offset higher research development costs company realigned allocations research development costs based project spend attributable segments unfavorable foreign currency Corporate Certain income expense amounts allocated segment These amounts detailed table Note 14 within Item 1 primarily include net interest expense foreign exchange fluctuations principally relating intercompany receivables payables loans denominated foreign currency majority foreign currency hedging activities corporate headquarters costs 27 stock compensation expense non-strategic investments related income expense certain employee benefit plan costs well certain nonrecurring gains losses charges business optimization integration separation-related costs asset impairments Income Taxes The company effective income tax rate continuing operations 16.8 1.7 first quarters 2017 2016 respectively The company effective income tax rate differs U.S federal statutory rate year due certain operations subject tax incentives state local taxes foreign taxes different U.S federal statutory rate In addition effective tax rate impacted period discrete factors events The effective income tax rate continuing operations increased three months ended March 31 2017 principally due absence tax-free net realized gains associated Baxalta debt-for-equity exchanges benefits attributable closing IRS German income tax audit reflected three months ended March 31 2016 The effective income tax rate continuing operations three months ended March 31 2017 favorably impacted approximately 5.0 percentage points due tax windfall benefits realized stock option exercises vesting restricted share units performance share units associated company stock compensation programs Income Continuing Operations Earnings per Diluted Share Income continuing operations 273 million 0.50 per diluted share first quarter 2017 3.4 billion 6.13 per diluted share first quarter 2016 The significant factors events contributing changes discussed Loss Discontinued Operations Discontinued operations insignificant periods presented Refer Note 2 within Item 1 additional information regarding separation Baxalta LIQUIDITY AND CAPITAL RESOURCES The following table summary statement cash flow three month periods ended March 31 2017 2016 Three months ended March 31 millions 2017 2016 Cash flows operations continuing operations 206 174 Cash flows investing activities continuing operations 117 214 Cash flows financing activities 37 510 Cash Flows Operations Continuing Operations Operating cash flows continuing operations increased first quarter 2017 compared prior year period The increase driven factors discussed Accounts Receivable Cash inflows accounts receivable 78 million first quarter 2017 compared 16 million prior year days sales outstanding decreased 60.3 52.4 days quarter quarter This decrease primarily driven improved timing collections Europe Latin America 28 Inventories Cash outflows relating inventories increased slightly 2017 compared prior year period The following summary inventories March 31 2017 December 31 2016 well annualized inventory turns first quarter 2017 2016 segment Inventories Annualized inventory turns three March 31 December 31 months ended March 31 millions except inventory turn data 2017 2016 2017 2016 Renal 629 544 3.39 3.47 Hospital Products 851 885 3.89 3.01 Other 1 n/a n/a Total company 1,480 1,430 3.68 3.19 The increase inventories driven primarily seasonal inventory build Renal segment anticipation plant line maintenance partially offset decline Hospital Products segment driven continued working capital improvement initiatives strong U.S sales segment Fluid Systems Surgical Care businesses Other The changes accounts payable accrued liabilities 262 million outflow first quarter 2017 compared 438 million outflow first quarter 2016 The changes primarily driven first quarter 2016 non-recurring 303 million tax settlement payment partially settle U.S Federal income tax audit well timing supplier payments Payments related execution company business optimization initiatives increased 22 million first quarter 2016 43 million first quarter 2017 The company made payments 12 million first quarter 2016 related execution COLLEAGUE infusion pump SIGMA SPECTRUM infusion pump recalls Refer Note 7 within Item 1 information regarding company business optimization initiatives Changes balance sheet items outflows 62 million 108 million first quarter 2017 2016 respectively primarily driven changes prepaid expenses Cash Flows Investing Activities Continuing Operations Capital Expenditures Capital expenditures 123 million 184 million first quarters 2017 2016 respectively The company capital expenditures 2017 driven targeted investments projects support production PD IV solutions Acquisitions Investments Cash outflows relating acquisitions investments significant first quarter 2017 Cash outflows relating acquisitions investments 33 million first quarter 2016 driven primarily acquisition rights Vancomycin Celerity Divestitures Other Investing Activities Cash inflows divestitures investing activities significant first quarters 2017 2016 Cash Flows Financing Activities Debt Issuances Net Payments Obligations There cash flows related debt financing obligations first quarter 2017 Net cash inflows related debt financing obligations totaled 491 million first quarter 2016 primarily related 61 million borrowings company revolving credit facility 450 million issuance commercial paper 29 Other Financing Activities Cash dividend payments totaled 70 million 63 million first quarters 2017 2016 respectively The increase cash dividend payments primarily due increase quarterly dividend rate 0.115 0.13 per share quarterly dividends beginning May 2016 Proceeds stock issued employee benefit plans increased 84 million first quarter 2016 111 million first quarter 2017 primarily due increased option exercises first quarter 2017 As authorized Board Directors company repurchases stock depending upon company cash flows net debt level market conditions In July 2012 Board Directors authorized repurchase 2.0 billion company common stock The Board Directors increased authority additional 1.5 billion November 2016 The company paid 51 million cash repurchase approximately 1 million shares pursuant authority first quarter 2017 1.6 billion remaining available authorization March 31 2017 The company repurchase stock first quarter 2016 Credit Facilities Access Capital Credit Ratings Credit Facilities As March 31 2017 company U.S dollar-denominated revolving credit facility Euro-denominated senior revolving credit facility maximum capacity 1.5 billion approximately 200 million respectively As March 31 2017 company compliance financial covenants agreements The non-performance financial institution supporting either credit facilities would reduce maximum capacity facilities institution respective commitment Access Capital The company intends fund short-term long-term obligations mature cash hand future cash flows operations issuing additional debt The company 2.9 billion cash equivalents March 31 2017 adequate cash available meet operating requirements jurisdiction company operates The company invests excess cash certificates deposit money market funds diversifies concentration cash among different financial institutions The company ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company products solvency customers suppliers deterioration company key financial ratios credit ratings significantly unfavorable changes conditions However company believes sufficient financial flexibility issue debt enter financing arrangements attract long-term capital acceptable terms support company growth objectives The company continues business foreign governments certain countries including Greece Spain Portugal Italy experienced deterioration credit economic conditions As March 31 2017 company net accounts receivable public sector Greece Spain Portugal Italy totaled 142 million While economic conditions significantly impacted company ability collect receivables global economic conditions liquidity issues certain countries resulted may continue result delays collection receivables credit losses Credit Ratings The company credit ratings March 31 2017 follows Standard Poor Fitch Moody Ratings Senior debt A BBB Baa2 Short-term debt A2 F2 P2 Outlook Stable Stable Stable 30 CRITICAL ACCOUNTING POLICIES The preparation financial statements accordance GAAP requires management make estimates judgments affect reported amounts assets liabilities revenues expenses A summary company significant accounting policies included Note 1 company consolidated financial statements 2016 Annual Report Certain company accounting policies considered critical policies important depiction company financial statements require significant difficult complex judgments often employing use estimates effects matters inherently uncertain Such policies summarized Management Discussion Analysis Financial Condition Results Operations section 2016 Annual Report There significant changes company application critical accounting policies first quarter 2017 LEGAL CONTINGENCIES Refer Note 13 within Item 1 discussion company legal contingencies Upon resolution uncertainties company may incur charges excess presently established liabilities While liability company connection certain claims cannot estimated certainty although resolution reporting period one matters could significant impact company results operations cash flows period outcome legal proceedings expected material adverse effect company consolidated financial position While company believes valid defenses matters litigation inherently uncertain excessive verdicts occur company may future incur material judgments enter material settlements claims CERTAIN REGULATORY MATTERS In January 2014 company received Warning Letter FDA primarily directed quality systems company Round Lake Illinois facility particularly facility capacity specification developer certain company medical devices This Warning Letter lifted February 2017 The company received Warning Letter December 2013 included observations related company ambulatory infuser business Irvine California previously subject agency action In June 2013 company received Warning Letter FDA regarding operations processes North Cove North Carolina Jayuya Puerto Rico facilities November 2015 attended Regulatory Meeting FDA concerning Jayuya facility The Warning Letter addresses observations related Current Good Manufacturing Practice violations two facilities In June 2010 company received Warning Letter FDA connection inspection McGaw Park Illinois facility previously supported Renal franchise The company Round Lake facility provides related capacity Renal franchise The Warning Letter pertains processes company analyzes addresses product complaints corrective preventative action reports relevant information FDA This Warning Letter lifted February 2017 On October 9 2014 company Regulatory Meeting FDA discuss Warning Letters described At meeting company agreed work closely FDA provide regular updates progress meet requirements resolve matters identified Warning Letters described Please see Item 1A 2016 Annual Report Item 1 Part II quarterly report additional discussion regulatory matters may impact company FORWARD-LOOKING INFORMATION This quarterly report includes forward-looking statements Use words may would could believes estimates projects potential expects plans seeks intends evaluates pursues anticipates continues designs impacts affects forecasts target outlook initiative objective designed priorities goal negative words similar expressions intended identify forward-looking statements represent current judgment possible future events These forward-looking statements may include statements respect accounting estimates assumptions litigation-related matters including outcomes future regulatory filings company R&D pipeline strategic objectives credit exposure foreign governments potential developments respect credit ratings investment foreign earnings estimates liabilities including related uncertain tax positions contingent payments future pension plan contributions costs discount rates rates return company exposure financial market volatility foreign currency interest rate risks potential tax liability associated separation company biopharmaceuticals medical products businesses including 2016 disposition company retained stake Baxalta impact competition future sales growth business development activities business optimization initiatives cost saving initiatives future capital R&D expenditures future 31 debt issuances manufacturing expansion sufficiency company facilities financial flexibility adequacy credit facilities tax provisions reserves effective tax rate statements relate historical facts These forward-looking statements based certain assumptions analyses made light company experience perception historical trends current conditions expected future developments well factors company believes appropriate circumstances While statements represent company current judgment future may hold company believes judgments reasonable statements guarantees events financial results Whether actual future results developments conform expectations predictions subject number risks uncertainties including following factors many beyond control failure achieve long-term financial improvement goals demand market acceptance risks competitive pressures related new existing products impact products quality patient safety concerns product development risks including satisfactory clinical performance ability manufacture appropriate scale general unpredictability associated product development cycle product quality patient safety issues leading product recalls withdrawals launch delays sanctions seizures litigation declining sales future actions FDA EMA regulatory body government authority including U.S Department Justice New York Attorney General could delay limit suspend product development manufacturing sale result seizures recalls injunctions monetary sanctions criminal civil liabilities failures respect company compliance programs future actions third parties including third-party payers healthcare reform similar measures implemented modified repealed United States globally impact ongoing U.S healthcare reform similar actions undertaken foreign governments respect pricing reimbursement taxation rebate policies additional legislation regulation governmental pressures United States globally may affect pricing reimbursement taxation rebate policies government agencies private payers elements company business impact competitive products pricing including generic competition drug reimportation disruptive technologies global regulatory trade tax policies company ability identify business development growth opportunities successfully execute business development strategies company ability finance develop new products enhancements internally commercially acceptable terms availability pricing acceptable raw materials component supply inability create additional production capacity timely manner occurrence manufacturing supply difficulties impact future tax liability respect separation distribution including respect disposition Retained Shares failure Baxalta Shire satisfy obligation separation agreements including tax matters agreement company letter agreement Shire Baxalta ability protect enforce company owned in-licensed patent proprietary rights including trademarks copyrights trade secrets know-how patents third parties preventing restricting company manufacture sale use affected products technology impact global economic conditions company customers suppliers including foreign governments certain countries company operates fluctuations foreign exchange interest rates 32 changes law concerning taxation income including income earned outside United States may part comprehensive tax reform actions tax authorities connection ongoing tax audits breaches failures company information technology systems loss key employees inability identify recruit new employees outcome pending future litigation adequacy company cash flows operations meet ongoing cash obligations fund investment program factors identified elsewhere report filings Securities Exchange Commission including factors described Item 1A company Annual Report Form 10-K year ended December 31 2016 available company website Actual results may differ materially projected forward-looking statements The company undertake update forward-looking statements Item 3 Quantitative Qualitative